← All trials
NCT05577312
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2022
- Primary completion
- Aug 4, 2025
- Completion date
- Sep 10, 2026
- First posted
- Oct 13, 2022
- Last posted
- Nov 10, 2022
- Enrollment
- 9
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Bioray Laboratory Inc.Lead sponsor
- Shanghai Bioray Laboratory Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.